ECSP21060868A - 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión - Google Patents

5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Info

Publication number
ECSP21060868A
ECSP21060868A ECSENADI202160868A ECDI202160868A ECSP21060868A EC SP21060868 A ECSP21060868 A EC SP21060868A EC SENADI202160868 A ECSENADI202160868 A EC SENADI202160868A EC DI202160868 A ECDI202160868 A EC DI202160868A EC SP21060868 A ECSP21060868 A EC SP21060868A
Authority
EC
Ecuador
Prior art keywords
disorder
dimethyltryptamine
dmt
meo
depression
Prior art date
Application number
ECSENADI202160868A
Other languages
English (en)
Inventor
Theis Terwey
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65529503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21060868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of ECSP21060868A publication Critical patent/ECSP21060868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones para su uso en el tratamiento de un paciente que padece un trastorno mental en particular trastorno depresivo mayor, trastorno depresivo persistente, trastorno de ansiedad, trastorno de estrés postraumático, trastorno dismórfico corporal, trastorno obsesivo compulsivo, trastorno alimentario y abuso de sustancias psicoactivas. Se proporcionan además regímenes de dosificación para tratar estos trastornos.
ECSENADI202160868A 2019-02-22 2021-08-17 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión ECSP21060868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22

Publications (1)

Publication Number Publication Date
ECSP21060868A true ECSP21060868A (es) 2021-11-30

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202160868A ECSP21060868A (es) 2019-02-22 2021-08-17 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Country Status (32)

Country Link
US (2) US20220071958A1 (es)
EP (3) EP4353314B1 (es)
JP (2) JP7598326B2 (es)
KR (1) KR20210154966A (es)
CN (1) CN114555078A (es)
AU (2) AU2020225410B2 (es)
BR (1) BR112021016153A2 (es)
CA (1) CA3130406A1 (es)
CL (1) CL2021002174A1 (es)
CO (1) CO2021010882A2 (es)
CR (1) CR20210437A (es)
DK (3) DK4353314T3 (es)
DO (1) DOP2021000176A (es)
EA (1) EA202192318A1 (es)
EC (1) ECSP21060868A (es)
ES (2) ES2984438T3 (es)
FI (3) FI4349407T3 (es)
HR (2) HRP20250590T1 (es)
HU (2) HUE066828T2 (es)
IL (1) IL285537A (es)
LT (2) LT3927337T (es)
MA (1) MA55021B1 (es)
MD (1) MD3927337T2 (es)
MX (2) MX2021009941A (es)
NI (1) NI202100080A (es)
PE (1) PE20220015A1 (es)
PL (2) PL4349407T3 (es)
PT (2) PT4349407T (es)
RS (2) RS66912B1 (es)
SI (2) SI3927337T1 (es)
SM (1) SMT202400154T1 (es)
WO (1) WO2020169850A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (en) * 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
HRP20220797T1 (hr) 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
CA3188263A1 (en) * 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
EP4138818B1 (en) * 2020-08-28 2024-08-21 Cybin UK Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4221682A2 (en) * 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (en) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
EP4255421A1 (en) * 2020-12-01 2023-10-11 Small Pharma Ltd Inhalable formulations
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CA3216889A1 (en) 2021-04-26 2022-11-03 Glenn Short Novel n,n-dimethyltryptamine compositions and methods
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
EP4333979A4 (en) * 2021-05-03 2025-01-15 Mind Medicine, Inc. Method of titrating dose of psychedelics
WO2022235927A1 (en) * 2021-05-05 2022-11-10 Gilgamesh Pharmaceuticals, Inc. Novel tryptamines and methods of treating mood disorders
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US20230064429A1 (en) 2021-08-19 2023-03-02 Mind Medicine, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4433049A1 (en) * 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
JP2025510368A (ja) 2022-03-27 2025-04-14 ジーエイチ・リサーチ・アイルランド・リミテッド 不安の処置
KR20250005182A (ko) 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
WO2023186834A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Crystalline hydrobromide salt of 5-meo-dmt
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
JP2026505778A (ja) 2023-01-30 2026-02-18 ジーエイチ・リサーチ・アイルランド・リミテッド 産後うつ病の処置における５－ｍｅｏ－ｄｍｔの使用
CN120813348A (zh) 2023-01-30 2025-10-17 Gh研究爱尔兰有限公司 用于治疗产后抑郁的5-甲氧基-n,n-二甲基色胺
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
WO2024251807A1 (en) * 2023-06-08 2024-12-12 Cybin Irl Limited Companion animal treatments
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
EP4784121A1 (en) * 2023-09-28 2026-08-05 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
AU2024367931A1 (en) 2023-10-23 2026-02-26 Reconnect Labs Ag Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses
CN122477041A (zh) * 2023-11-22 2026-07-28 吉尔伽美什制药公司 使用n-乙基-2-(5-氟-1h-吲哚-3-基)-n-甲基乙-1-胺或其药学上可接受的盐治疗心境障碍患者
WO2026068951A1 (en) * 2024-09-27 2026-04-02 Beckley Psytech Limited 5-methoxy-dmt for use in the treatment of depression
WO2026078143A1 (en) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression
WO2026162814A1 (en) 2025-02-02 2026-08-06 GH Research Ireland Limited Treatment regimens with mebufotenin for treating major depressive disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20040127409A1 (en) 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
DE502006008441D1 (de) 2006-08-01 2011-01-13 Stobi Gmbh & Co Kg Ventilballon für Inhalatoren
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére

Also Published As

Publication number Publication date
AU2020225410B2 (en) 2025-10-30
WO2020169850A1 (en) 2020-08-27
EP4353314B1 (en) 2026-06-24
US20240307350A1 (en) 2024-09-19
PL4349407T3 (pl) 2025-07-21
CR20210437A (es) 2021-11-02
DK4353314T3 (da) 2026-07-13
AU2026200720A1 (en) 2026-02-19
EP4349407B1 (en) 2025-04-09
CA3130406A1 (en) 2020-08-27
EA202192318A1 (ru) 2021-12-21
NI202100080A (es) 2021-12-06
ES3031965T3 (en) 2025-07-14
CO2021010882A2 (es) 2022-01-17
DK3927337T3 (da) 2024-04-22
SI3927337T1 (sl) 2024-07-31
EP3927337B1 (en) 2024-02-14
EP3927337B8 (en) 2024-03-20
HUE066828T2 (hu) 2024-09-28
RS65706B1 (sr) 2024-08-30
EP4349407A2 (en) 2024-04-10
JP2025029035A (ja) 2025-03-05
MA55021A (fr) 2021-12-29
ES2984438T3 (es) 2024-10-29
US20220071958A1 (en) 2022-03-10
PL3927337T3 (pl) 2024-07-29
EP4353314A3 (en) 2024-07-03
RS66912B1 (sr) 2025-07-31
MX2025002567A (es) 2025-04-02
FI4353314T3 (fi) 2026-07-28
BR112021016153A2 (pt) 2021-10-05
PT3927337T (pt) 2024-05-17
SI4349407T1 (sl) 2025-06-30
PT4349407T (pt) 2025-06-04
AU2020225410A1 (en) 2021-08-19
LT4349407T (lt) 2025-07-10
HRP20240532T1 (hr) 2024-07-19
JP2022521337A (ja) 2022-04-06
EP3927337A1 (en) 2021-12-29
MD3927337T2 (ro) 2024-08-31
CN114555078A (zh) 2022-05-27
FI3927337T3 (fi) 2024-05-08
JP7598326B2 (ja) 2024-12-11
DOP2021000176A (es) 2021-11-21
MA55021B1 (fr) 2024-05-31
EP4353314A2 (en) 2024-04-17
IL285537A (en) 2021-09-30
HUE071841T2 (hu) 2025-09-28
PE20220015A1 (es) 2022-01-11
HRP20250590T1 (hr) 2025-07-04
KR20210154966A (ko) 2021-12-21
SMT202400154T1 (it) 2024-07-09
LT3927337T (lt) 2024-07-10
FI4349407T3 (fi) 2025-06-02
CL2021002174A1 (es) 2022-01-28
MX2021009941A (es) 2021-12-10
EP4349407A3 (en) 2024-07-03
DK4349407T3 (da) 2025-05-26

Similar Documents

Publication Publication Date Title
DOP2021000176A (es) 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión
CO2021010883A2 (es) Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
MX2017015186A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
MX2019011606A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX387839B (es) Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
CO2021008187A2 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
MX2022014199A (es) Usos y formulaciones de los cannabinoides.
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
JOP20250311A1 (ar) مثبطات tyk2 وتركيبات وطرق لها
BR112018009476A8 (pt) regime de dosagem de plasminogênio para cicatrização de ferimentos
CL2022001167A1 (es) Tratamiento de trastornos hepáticos
CL2019003172A1 (es) Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.
CL2022001476A1 (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
BR112018015483A2 (pt) formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
MX2022005375A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
EP4084869A4 (en) Composition and therapy for treatment of gag reflexes
EA201892830A1 (ru) Применение ксиборнола в качестве активного агента для лечения вирусных инфекций
EA202190660A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2025001006A1 (es) Uso de enavogliflozina para tratar o prevenir nefropatía.
AR117329A1 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica